Collier Neurologic Specialists | Naples, FL
Status and phase
Conditions
Treatments
About
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER
Full description
This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU838 in adult patients with PMS. The study will consist of the following periods:
Screening Period: Approximately 28 days Main Treatment Period: Up to 120 weeks (approximately 2 years) Open Label Extension Period: Up to approximately 8 years
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adult patients, age 18 to 65 years (inclusive).
EDSS score at screening between 3.0 to 6.5 (both inclusive)
No evidence of relapse in the last 24 months before randomization, AND Patients diagnosed according to 2017 revised McDonald Criteria 1 and the 2013 revised classification of disease courses 2 as either
Willingness and ability to comply with the protocol.
Written informed consent given by the patient before the beginning of any study-related procedure.
Documented evidence of disability progression not temporarily related to a relapse in the last 24 months before randomization, adjudicated by a central independent reviewer
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
450 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Andreas Muehler, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal